Metabolic Positron Emission Tomography in Breast Cancer.
Breast cancer
Fluorodeoxyglucose (FDG)
PET/CT
Positron emission tomography (PET)
Journal
PET clinics
ISSN: 1879-9809
Titre abrégé: PET Clin
Pays: United States
ID NLM: 101260152
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
medline:
4
9
2023
pubmed:
28
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
Metabolic PET, most commonly 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT), has had a major impact on the imaging of breast cancer and can have important clinical applications in appropriate patients. While limited for screening, FDG PET/CT outperforms conventional imaging in locally advanced breast cancer. FDG PET/CT is more sensitive than conventional imaging in assessing treatment response, accurately predicting complete response or nonresponse in early-stage cases. It also aids in determining disease extent and treatment response in the metastatic setting. Further research, including randomized controlled trials with FDG and other metabolic agents such as fluciclovine, is needed for optimal breast cancer imaging.
Identifiants
pubmed: 37369614
pii: S1556-8598(23)00036-6
doi: 10.1016/j.cpet.2023.04.004
pii:
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Radiopharmaceuticals
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
473-485Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.